G8749 Absence of signs of melanoma (tenderness, jaundice, localized neurologic signs such as weakness, or any other sign suggesting systemic spread) or absence of symptoms of melanoma (cough, dyspnea, pain, paresthesia, or any other symptom suggesting the possibility of systemic spread of melanoma)

Short descriptor: No signs melanoma

✓ Active HCPCS Level II 2026
Open G8749 in the app →

Look up G8749 alongside ICD-10-CM diagnoses, the HCPCS Table of Drugs, and the AI coding assistant.

G8749 is the HCPCS Level II code for Absence of signs of melanoma (tenderness, jaundice, localized neurologic signs such as weakness, or any other sign suggesting systemic spread) or absence of symptoms of melanoma (cough, dyspnea, pain, paresthesia, or any other symptom suggesting the possibility of systemic spread of melanoma) (2026). It belongs to Section G — Procedures / Professional Services (Temporary). Under Medicare, its coverage status is: Carrier judgment. Part B pricing methodology: Not separately priced by Part B.

Classification & CMS Attributes

Medicare Coverage
Carrier judgment (code C)
Part B Pricing
Not separately priced by Part B (indicator 00)
Type of Service
Medical care
Effective Date
2019-01-01
2026 Maintenance
No change this year

References

Cite This Page

Reference G8749 with the canonical source and edition:

G8749 — Absence of signs of melanoma (tenderness, jaundice, localized neurologic signs such as weakness, or any other sign suggesting systemic spread) or absence of symptoms of melanoma (cough, dyspnea, pain, paresthesia, or any other symptom suggesting the possibility of systemic spread of melanoma). ICD-10 Coding Pro (HCPCS Level II 2026). https://icd10codingpro.com/hcpcs-codes/G8749

Canonical URL: https://icd10codingpro.com/hcpcs-codes/G8749

Related Codes in Section G

Browse all HCPCS Level II sections →
Reviewed by Prajwal Shrestha, CPC, CRC
Certified Professional Coder (CPC) and Certified Risk Adjustment Coder (CRC) · AAPC Member ID 01997614 · About · Editorial policy · Content last reviewed: 2026-01-01

Get HCC Mappings, Clinical Summaries, and More

Access premium features including HCC risk adjustment, FDA drug indications, AI coding assistant, and comprehensive clinical context.

Start Free Trial